


# Donor 6323

# **Genetic Testing Summary**



Last Updated: 09/28/20

Donor Reported Ancestry: Irish, African American

Jewish Ancestry: No

Genetic Test*	Result	Comments/Donor's Residual Risk**

Chromosome analysis (karyotype)	Normal male karyotype	No evidence of clinically significant chromosome abnormalities
Hemoglobin evaluation	Normal hemoglobin fractionation and MCV/MCH results	Reduced risk to be a carrier for sickle cell anemia, beta thalassemia, alpha thalassemia trait (aa/ and a-/a-) and other hemoglobinopathies
Cystic Fibrosis (CF) carrier screening	Negative by gene sequencing in the CFTR gene	1/440
Expanded Genetic Disease Carrier Screening Panel attached- 283 diseases by gene sequencing	Carrier: Alpha Thalassemia (HBA1/HBA2)- Silent carrier aa/-a Increased risk to be a carrier: Spinal Muscular Atrophy (SMN1/SMN2) Carrier risk is 1/23- see report Negative for other genes sequenced	Partner testing recommended before using this donor.

\*No single test can screen for all genetic disorders. A negative screening result significantly reduces, but cannot eliminate, the risk for these conditions in a pregnancy.

\*\*Donor residual risk is the chance the donor is still a carrier after testing negative.





# Patient Information Name: 6323 Donor Date of Birth: Sema4 ID: Client ID: Indication: Carrier Testing

#### **Specimen Information**

Specimen Type: Blood Date Collected: 04/28/2020 Date Received: 04/29/2020 Final Report: 05/13/2020

# Referring Provider

Fairfax Cryobank, Inc.



# Expanded Carrier Screen (283) Minus TSE

Number of genes tested: 283

# SUMMARY OF RESULTS AND RECOMMENDATIONS

	⊖ Negative
<b>Carrier of Alpha-Thalassemia (AR)</b> Associated gene(s): <i>HBA1/HBA2</i> Variant(s) Detected: One copy of the alpha 3.7 deletion	<b>Negative for all other genes tested</b> To view a full list of genes and diseases tested please see Table 1 in this report
Increased Risk of being a Silent (2+0) Carrier of Spinal Muscular Atrophy (AR) Associated gene(s): <i>SMN1</i> Variant(s) Detected: c.*3+80T>G positive with 2 copies of <i>SMN1</i>	

AR=Autosomal recessive; XL=X-linked

# Recommendations

- Testing the partner for the above positive disorder(s) and genetic counseling are recommended.
- Please note that for female carriers of X-linked diseases, follow-up testing of a male partner is not indicated.
- CGG repeat analysis of *FMR1* for fragile X syndrome is not performed on males as repeat expansion of premutation alleles is not expected in the male germline.
- Individuals of Asian, African, Hispanic and Mediterranean ancestry should also be screened for hemoglobinopathies by CBC and hemoglobin electrophoresis.
- Consideration of residual risk by ethnicity after a negative carrier screen is recommended for the other diseases on the panel, especially in the case of a positive family history for a specific disorder.





# Interpretation of positive results

# Alpha-Thalassemia (AR)

# **Results and Interpretation**

HBA1 Copy Number: 2 HBA2 Copy Number: 1 One copy of the alpha 3.7 deletion detected HBA1/HBA2 Sequencing: Negative Gene(s) analyzed: HBA1 (NM\_000558.4) and HBA2 (NM\_000517.4)

# Inheritance: Autosomal Recessive

This patient carries a heterozygous alpha 3.7 deletion, resulting in the loss of one copy of the alpha-globin gene and is therefore a silent carrier of alpha-thalassemia (aa/-a). No pathogenic or likely pathogenic variants were identified by sequence analysis.

Typically, individuals have four functional alpha-globin genes: 2 copies of *HBA1* and 2 copies of *HBA2*, whose expression is regulated by a cisacting regulatory element HS-40. Alpha-thalassemia carriers have three (silent carrier) or two (carrier of the alpha-thalassemia trait) functional alpha-globin genes with or without a mild phenotype.

# What is Alpha-Thalassemia?

Alpha-thalassemia is an autosomal recessive condition that affects the red blood cells. It can affect people of any ethnicity, but is more common in people who can trace their ancestry to Southeast Asia, India, equatorial Africa, the Mediterranean, or the Arabian Peninsula. There are two major forms of alpha-thalassemia:

- Hemoglobin Bart syndrome is caused by a loss of all 4 alpha-globin genes (--/--). It is very severe, and fetuses are either stillborn or die shortly after birth.
- Alpha-thalassemia (also called HbH disease) is caused by a loss of 3 alpha-globin genes (-a/--). This disease results in anemia, an enlarged spleen, and mild jaundice. Most individuals are mildly disabled by this condition. Some people with more severe disease require frequent blood transfusions.

The type of disease as well as the severity of symptoms can be predicted based on the genetic variants detected. Carriers may have mild anemia.

# Spinal Muscular Atrophy (AR)

#### **Results and Interpretation**

*SMN1* copy number: 2 *SMN2* copy number: 2

c.\*3+80T>G: Detected

Gene(s) analyzed: SMN1 (NM\_000344.3) and SMN2 (NM\_017411.3)

# Inheritance: Autosomal Recessive

This patient is negative for loss of *SMN1* copy number. Complete loss of *SMN1* is causative in spinal muscular atrophy (SMA). Two copies of *SMN1* were detected in this individual, which is considered a negative copy number result. However, parallel testing to assess the presence of an *SMN1* duplication allele was also performed to detect a single nucleotide polymorphism (SNP), c.\*3+80T>G, in intron 7 of the *SMN1* gene. This individual was found to be positive for this change and is therefore, at an increased risk of being a silent (2+0) carrier. See *SMA Table* for residual risk estimates based on ethnicity.

#### SMA Table: Carrier detection and residual risk estimates before and after testing for c.\*3+80T>G

African 1 in 85 71% 1 in 160 91% 1 in 455 1 in 49	Ethnicity	Carrier Frequency	Detection rate	Residual risk after negative result*	Detection rate with SMN1 c.*3+80T>G	Residual risk c.*3+80T>G negative	Residual risk c.*3+80T>G positive
		1 in 85	71%	1 in 160	91%	1 in 455	1 in 49





Ashkenazi Jewish	1 in 76	90%	1 in 672	93%	1 in 978	1 in 10
East Asian	1 in 53	94%	1 in 864	95%	1 in 901	1 in 12
European (Non- Finnish)	1 in 48	95%	1 in 803	95%	1 in 894	1 in 23
Native American	1 in 63	91%	1 in 609	94%	1 in 930	1 in 47
South Asian	1 in 103	87%	1 in 637	87%	1 in 637	1 in 608
Sephardic Jewish	1 in 34	96%	1 in 696	97%	1 in 884	1 in 12

\*Residual risk with two copies *SMN1* detected using dosage sensitive methods. The presence of three or more copies of *SMN1* reduces the risk of being an *SMN1* carrier between 5 - 10 fold, depending on ethnicity.

FOR INDIVIDUALS WITH MIXED ETHNICITY, USE HIGHEST RESIDUAL RISK ESTIMATE

^ Parental follow-up will be requested for confirmation

#### What is spinal muscular atrophy?

Spinal muscular atrophy (SMA) is a pan-ethnic, autosomal recessive disease caused by loss of function of the *SMN1* gene. In over 95% of cases, patients are missing both copies of the *SMN1* gene. The disease is characterized by the degeneration of alpha motor neurons of the spinal cord anterior horn cells, leading to progressive symmetric weakness, atrophy of the proximal voluntary muscles and early death. Age of onset can be anywhere on a continuum from the prenatal period to adulthood.

- SMA 0 represents the most severe form. Infants are born with severe hypotonia and joint contractures; no motor milestones are achieved and patients die before 6 months of age.
- SMA I has an age of onset in the first six months of life. These cases are associated with death usually by age 2 and the lack of development of motor skills.
- SMA II has an age of onset between 3 and 15 months; patients may be able to sit independently. Intelligence is not affected. Life expectancy may vary from early childhood to early adulthood.
- SMA III has an age of onset after 18 months of age and as late as adolescence; patients may learn to stand and to walk short distances. These patients may have a normal lifespan.
- SMA IV is an adult-onset disorder of muscle weakness; life span is not shortened.

Most patients, regardless of the severity of disease, have a deletion of both *SMN1* copies. Patients with later-onset disease usually have three or more copies of *SMN2*, which encodes a small amount of residual protein and lessens the severity of the symptoms. However, other factors besides *SMN2* copy number may affect the phenotype, and therefore the severity of the disease may not be able to be accurately predicted in all patients based on genotype.

# Test description

This patient was tested for a panel of diseases using a combination of sequencing, targeted genotyping and copy number analysis. Please note that negative results reduce but do not eliminate the possibility that this individual is a carrier for one or more of the disorders tested. Please see Table 1 for a list of genes and diseases tested, and **go.sema4.com/residualrisk** for specific detection rates and residual risk by ethnicity. With individuals of mixed ethnicity, it is recommended to use the highest residual risk estimate. Only variants determined to be pathogenic or likely pathogenic are reported in this carrier screening test.

# sema4



lino

Ruth Kornreich, Ph.D., FACMG, Laboratory Director Laboratory Medical Consultant: George A. Diaz, M.D., Ph.D.

# Genes and diseases tested

For specific detection rates and residual risk by ethnicity, please visit go.sema4.com/residualrisk

# Table 1: List of genes and diseases tested with detailed results

	Disease	Gene	Inheritance Pattern	Status	Detailed Summary
Ð	Positive				
	Alpha-Thalassemia	HBA1/HBA2	AR	Silent Carrier	<i>HBA1</i> Copy Number: 2 <i>HBA2</i> Copy Number: 1 One copy of the alpha 3.7 deletion detected <i>HBA1/HBA2</i> Sequencing: Negative
	Spinal Muscular Atrophy	SMN1	AR	Increased Risk	<i>SMN1</i> copy number: 2 <i>SMN2</i> copy number: 2 c.*3+80T>G: Detected
Θ	Negative				
	3-Beta-Hydroxysteroid Dehydrogenase Type II Deficiency	HSD3B2	AR	Reduced Risk	
	3-Methylcrotonyl-CoA Carboxylase Deficiency ( <i>MCCC1</i> - Related)	MCCC1	AR	Reduced Risk	
	3-Methylcrotonyl-CoA Carboxylase Deficiency ( <i>MCCC2</i> - Related)	MCCC2	AR	Reduced Risk	
	3-Methylglutaconic Aciduria, Type III	OPA3	AR	Reduced Risk	
	3-Phosphoglycerate Dehydrogenase Deficiency	PHGDH	AR	Reduced Risk	
	6-Pyruvoyl-Tetrahydropterin Synthase Deficiency	PTS	AR	Reduced Risk	
	Abetalipoproteinemia	MTTP	AR	Reduced Risk	
	Achromatopsia (CNGB3-related)	CNGB3	AR	Reduced Risk	
	Acrodermatitis Enteropathica	SLC39A4	AR	Reduced Risk	
	Acute Infantile Liver Failure	TRMU	AR	Reduced Risk	
	Acyl-CoA Oxidase I Deficiency	ACOX1	AR	Reduced Risk	
	Adenosine Deaminase Deficiency	ADA	AR	Reduced Risk	
	Adrenoleukodystrophy, X-Linked	ABCD1	XL	Reduced Risk	
	Aicardi-Goutieres Syndrome (SAMHD1-Related)	SAMHD1	AR	Reduced Risk	
_	Alpha-Mannosidosis	MAN2B1	AR	Reduced Risk	
	Alpha-Thalassemia Mental Retardation Syndrome	ATRX	XL	Reduced Risk	
	Alport Syndrome (COL4A3-Related)	COL4A3	AR	Reduced Risk	





Alport Syndrome (COL4A4-Related)	COL4A4	AR	Reduced Risk
Alport Syndrome (COL4A5-Related)	COL4A5	XL	Reduced Risk
Alstrom Syndrome	ALMS1	AR	Reduced Risk
Andermann Syndrome	SLC12A6	AR	Reduced Risk
Argininosuccinic Aciduria	ASL	AR	Reduced Risk
Aromatase Deficiency	CYP19A1	AR	Reduced Risk
Arthrogryposis, Mental Retardation, and Seizures	SLC35A3	AR	Reduced Risk
Asparagine Synthetase Deficiency	ASNS	AR	Reduced Risk
Aspartylglycosaminuria	AGA	AR	Reduced Risk
Ataxia With Isolated Vitamin E Deficiency	TTPA	AR	Reduced Risk
Ataxia-Telangiectasia	ATM	AR	Reduced Risk
Autosomal Recessive Spastic Ataxia of Charlevoix- Saguenay	SACS	AR	Reduced Risk
Bardet-Biedl Syndrome (BBS10-Related)	BBS10	AR	Reduced Risk
Bardet-Biedl Syndrome (BBS12-Related)	BBS12	AR	Reduced Risk
Bardet-Biedl Syndrome (BBS1-Related)	BBS1	AR	Reduced Risk
Bardet-Biedl Syndrome (BBS2-Related)	BBS2	AR	Reduced Risk
Bare Lymphocyte Syndrome, Type II	CIITA	AR	Reduced Risk
Bartter Syndrome, Type 4A	BSND	AR	Reduced Risk
Bernard-Soulier Syndrome, Type A1	GP1BA	AR	Reduced Risk
Bernard-Soulier Syndrome, Type C	GP9	AR	Reduced Risk
Beta-Globin-Related Hemoglobinopathies	HBB	AR	Reduced Risk
Beta-Ketothiolase Deficiency	ACAT1	AR	Reduced Risk
Bilateral Frontoparietal Polymicrogyria	GPR56	AR	Reduced Risk
Biotinidase Deficiency	BTD	AR	Reduced Risk
Bloom Syndrome	BLM	AR	Reduced Risk
Canavan Disease	ASPA	AR	Reduced Risk
Carbamoylphosphate Synthetase I Deficiency	CPS1	AR	Reduced Risk
Carnitine Palmitoyltransferase IA Deficiency	CPT1A	AR	Reduced Risk
Carnitine Palmitoyltransferase II Deficiency	CPT2	AR	Reduced Risk
Carpenter Syndrome	RAB23	AR	Reduced Risk
Cartilage-Hair Hypoplasia	RMRP	AR	Reduced Risk
Cerebral Creatine Deficiency Syndrome 1	SLC6A8	XL	Reduced Risk
Cerebral Creatine Deficiency Syndrome 2	GAMT	AR	Reduced Risk
Cerebrotendinous Xanthomatosis	CYP27A1	AR	Reduced Risk
Charcot-Marie-Tooth Disease, Type 4D	NDRG1	AR	Reduced Risk





Chreck-Main-Roch Diseas, X-Livied 9.892 N. Reduced Risk   Chreck-Main-Roch Diseas, X-Livied 9.893 A.R Reduced Risk   Chreck continuouteds 0.494 N. Reduced Risk   Chreck continuouted Diseas (C/28-Related) 0.494 A.R Reduced Risk   Chreck continuouted Diseas (C/28-Related) 0.494 A.R Reduced Risk   Chreck continuouted Diseas (C/28-Related) 0.493 A.R Reduced Risk   Chreck continuouted Diseas (C/28-Related) 0.493 Reduced Risk   Chreck continuouted Diseas (C/28-Related) 0.493 Reduced Risk   Chreck continuouted Diseas (C/28-Related) 0.493 Reduced Risk   Chreck continuouted Distance 0.493 Reduced Risk   Chreck continuouted Distance 0.493 Reduced Risk   Chreck continuouted Distance 0.494 Reduced Risk   Chrecher Distance 0.497 A.R Reduced Risk					
Chronesolarthocytosis     VPS3A     AR     Reduced Risk       Chronic Grandomaticus Dissaes (VPSA-Related)     C/184     AR     Reduced Risk       Chronic Grandomaticus Dissaes (VPSA-Related)     C/189     XL     Reduced Risk       Chronic Grandomaticus Dissaes (VPSA-Related)     C/189     XL     Reduced Risk       Chronic Grandomaticus Dissaes (VPSA-Related)     C/189     XL     Reduced Risk       Chronic Mandomaticus Dissaes (VPSA-Related)     C/189     XL     Reduced Risk       Chronic Mandomaticus Dissaes (VPSA-Related)     C/189     AR     Reduced Risk       Chronic Mathylmaticic Aciduris     ACSF3     AR     Reduced Risk       Combined Oxidatise Phospharylation Distionary 1     GPA4     AR     Reduced Risk       Combined Mathylmaticic Aciduris     ACSF3     AR     Reduced Risk       Combined Oxidatise Phospharylation Datidency 2     JPA9     AR     Reduced Risk       Combined Mathylmaticic Aciduris     C/P2/A4     R     Reduced Risk       Competital Admatal Hyperpleatis due to 7.Aptra- tyleaxyles Differency     JPA9     AR     Reduced Risk       Corgenital Mathylimaticic Admatal Hyperpleatis due to 7.Ap	Charcot-Marie-Tooth Disease, Type 5 / Arts Syndrome	PRPS1	XL	Reduced Risk	
Chrodidermia C/M XL Reduced Risk   Chronic Grandomatous Desses (C/SA-Related) C/RA AR Reduced Risk   Chronic Grandomatous Desses (C/SB-Related) C/RB XL Reduced Risk   Chronic Grandomatous Desses (C/SB-Related) C/RB XL Reduced Risk   Chronic Grandomatous Desses (C/SB-Related) C/RB AR Reduced Risk   Chronic Grandomatous Desses (C/SB-Related) ASS1 AR Reduced Risk   Chronic Grandomatous Desses (C/SB-Related) ASS1 AR Reduced Risk   Chronined Matoric and Methylmatoric Addutts ACS73 AR Reduced Risk   Combined Oxidative Phosphorybion Deficiency 1 GFM AR Reduced Risk   Combined Duttary Homone Deficiency 3 L/M3 AR Reduced Risk   Combined SAP Duficiency FSAP AR Reduced Risk   Comperital Adment Hyperplasis due to 21-Hydrorytese C/PE/AR Reduced Risk   Congenital Adment Hyperplasis due to 21-Hydrorytese C/PE/AR Reduced Risk   Congenital Adment Hyperplasis due to 21-Hydrorytese C/PE/AR Reduced Risk   Congenital Metroprisition CHRME-Related) M/R AR Reduced Risk   Congenital Metroprisition CHRME-Related) A/R Reduced Risk   Congenital Metropre	Charcot-Marie-Tooth Disease, X-Linked	GJB1	XL	Reduced Risk	
Chronic Granulomatous Desses (CVB4 Related)     CVBA     AR     Reduced Risk       Chronic Granulomatous Desses (CVB4 Related)     CVBB     XL     Reduced Risk       Chronic Granulomatous Desses (CVB4 Related)     CVBB     AR     Reduced Risk       Chrin Deficiency     SLDgAty     AR     Reduced Risk       Chronic Granulomatous Desses (CVB4 Related)     ACS73     AR     Reduced Risk       Combined Matchis and Methylinalonic Aciduta     ACS73     AR     Reduced Risk       Combined Oxidative Phosphorylation Deficiency 1     GFA1     AR     Reduced Risk       Combined Diffuency 2     PRO?     AR     Reduced Risk       Combined Phuthay Homono Deficiency 3     TSFM     AR     Reduced Risk       Combined Phuthay Homono Deficiency 3     LFA3     AR     Reduced Risk       Combined Staft Phosphorylation Deficiency 3     LFA3     AR     Reduced Risk       Combined Matchiers     CVF2242     AR     Reduced Risk       Compential Adversal Hyperplesia due to 21-Hydroylaso     CVF2242     AR     Reduced Risk       Corgential Adversal Hyperplesia due to 21-Hydroylaso     CVF2242     AR     <	Choreoacanthocytosis	VPS13A	AR	Reduced Risk	
Crocic Ganulomatous Disease (CYBP Related) CYBP Xi. Reduced Risk   Citin Daticiancy SL C25A12 AR Reduced Risk   Citin Daticiancy SL C25A12 AR Reduced Risk   Control Gradome VPS12B AR Reduced Risk   Control Matchic and Methylenkoic Aciduria ACSF3 AR Reduced Risk   Controlined Oxidative Phosphorylation Deficiency 1 GFM4 AR Reduced Risk   Controlined Oxidative Phosphorylation Deficiency 2 PROP1 AR Reduced Risk   Controlined Ritutary Hormono Daticiency 3 LFX3 AR Reduced Risk   Controlined SPD Deficiency PROP1 AR Reduced Risk   Controlined Altitutary Hormono Daticiency 3 LFX3 AR Reduced Risk   Comparital Adrenal Hyperplasia due to 2t-Mphre- Daticiancy PSAP AR Reduced Risk   Corregarital Adrenal Hyperplasia due to 2t-Mphre- Daticiancy RPAP AR Reduced Risk   Corregarital Adrenal Hyperplasia due to 2t-Mphre- Daticiancy RPAP AR Reduced Risk   Corregarital Edeced of Glococylation, Type b AMPL AR Reduced Risk   Corregarital Edeced of Glococylation, Type b ALG6 AR Reduced Risk   Corregarital Edeced of Glococylation, Type b ALG6	Choroideremia	СНМ	XL	Reduced Risk	
Circli Dublicition   SLC254/2   AR   Reduced Risk     Circli Dublicition   VPS12B   AR   Reduced Risk     Combined Materic and Methylmstoric Acidums   ACSF3   AR   Reduced Risk     Combined Materic and Methylmstoric Acidums   ACSF3   AR   Reduced Risk     Combined Oxidative Phosphorylation Daticiency 1   GPA4   AR   Reduced Risk     Combined Oxidative Phosphorylation Daticiency 2   PROP1   AR   Reduced Risk     Combined Oxidative Phosphorylation Daticiency 3   TSFM   AR   Reduced Risk     Combined Pitultary Hormone Deficiency 2   PROP1   AR   Reduced Risk     Comparital Adversal Hyperplasia due to 17-Alphae   PKP2   AR   Reduced Risk     Congenital Adversal Hyperplasia due to 21-Alphae   PKP2   AR   Reduced Risk     Congenital Adversal Hyperplasia due to 21-Alphae   PKP2   AR   Reduced Risk     Congenital Adversal Hyperplasia due to 21-Alphae   PKP2   AR   Reduced Risk     Congenital Closerd of Glycoxylation Type1   PKP2   AR   Reduced Risk     Congenital Edeced Figits   Corgenital Closerd ad figits   Corgenital Risk     Congenital Edeced of Glyc	Chronic Granulomatous Disease (CYBA-Related)	СҮВА	AR	Reduced Risk	
Citualizania, Type 1 ASS1 AR Reduced Risk   Cohen Syndrome VPS12/B AR Reduced Risk   Combined Malonic and Methylmateric Adduta ACS/3 AR Reduced Risk   Combined Oxidative Phosphoryletion Deficiency 1 GFM1 AR Reduced Risk   Combined Oxidative Phosphoryletion Deficiency 2 PROP1 AR Reduced Risk   Combined Oxidative Phosphoryletion Deficiency 2 PROP1 AR Reduced Risk   Combined SAP Deficiency PSAP AR Reduced Risk   Comportal Advent Physiphorylation Deficiency 2 PROP1 AR Reduced Risk   Comportal Advent Physiphorylation Deficiency 3 LHX3 AR Reduced Risk   Comportal Advent Physiphorylation Deficiency 3 LHX3 AR Reduced Risk   Congenital Advent Physiphorylation 1/1/Poeplasia due to 17-Alpha- Hydroxylase Deficiency CVP21/2 AR Reduced Risk   Congenital Advent Physiphorylasia due to 21-Hydroxylase Deficiency CVP21/2 AR Reduced Risk   Congenital Advent Physiphorylasia due to 21-Hydroxylase CVP21/2 CVP21/2   Congenital Advent Physiphorylasia due to 21-Hydroxylase AR Reduced Risk   Congenital Advent Physiphorylasia due to 21-Hydroxylase AR Reduced Risk   Congenital Advent Physiphorylasia due t	Chronic Granulomatous Disease (CYBB-Related)	CYBB	XL	Reduced Risk	
Cohen Synchrone     VPS13B     AR     Reduced Risk       Conbined Makric and Methylmatoric Acidutia     ACSF3     AR     Reduced Risk       Combined Oxidative Phosphorylation Deficiency 1     GFM1     AR     Reduced Risk       Combined Oxidative Phosphorylation Deficiency 2     PROP1     AR     Reduced Risk       Combined Oxidative Phosphorylation Deficiency 2     PROP1     AR     Reduced Risk       Combined SAP Deficiency 2     PROP1     AR     Reduced Risk       Combined SAP Deficiency 3     LHX3     AR     Reduced Risk       Compential Adhrenal Hyperplasia due to 27-Alpha- Hydraxylase Deficiency     PSAP     AR     Reduced Risk       Congenital Adhrenal Hyperplasia due to 21-Hydraxylase     CVP172A2     AR     Reduced Risk       Congenital Congenital Adhrenal Hyperplasia due to 21-Hydraxylase     PMM2     AR     Reduced Risk       Congenital Congenital Adhrenal Hyperplasia due to 21-Hydraxylase     PMM2     AR     Reduced Risk       Congenital Congenital Adhrenal Hyperplasia due to 21-Hydraxylase     PMM2     AR     Reduced Risk       Congenital Adhrenal Hyperplasia due to 21-Hydraxylase     PMM2     AR     Reduced Risk	Citrin Deficiency	SLC25A13	AR	Reduced Risk	
Combined Maloric and Methylmaloric Addulfa   ACSF3   AR   Reduced Risk     Combined Oxidiative Phosphorylation Deficiency 1   GF/41   AR   Reduced Risk     Combined Oxidiative Phosphorylation Deficiency 2   PROP1   AR   Reduced Risk     Combined Deficiency 3   LH/3   AR   Reduced Risk     Combined Phultary Homone Deficiency 3   LH/3   AR   Reduced Risk     Combined SAP Deficiency   PSAP   AR   Reduced Risk     Compertal Adrenal Hyperplasia due to 27-Alpha- Hydroxylase Deficiency   CYP21/AL   AR   Reduced Risk     Congental Adrenal Hyperplasia due to 27-Hydroxylase   CYP21/AL   AR   Reduced Risk   CYP21/AL copy number: 2 CYP21/A2 cop	Citrullinemia, Type 1	ASS1	AR	Reduced Risk	
Combined Oxidative Phosphorylation Deficiency 1   GPM at   AR   Reduced Risk     Combined Oxidative Phosphorylation Deficiency 2   FROP1   AR   Reduced Risk     Combined Phuthary Homone Deficiency 2   FROP1   AR   Reduced Risk     Combined Phuthary Homone Deficiency 3   LHX3   AR   Reduced Risk     Combined SVD Deficiency   FSAP   AR   Reduced Risk     Comportal Advenut Hyperplasia due to 27-Alphe- Hydraxylase Deficiency   CYP21AL   AR   Reduced Risk     Congental Adrenat Hyperplasia due to 27-Alphe- Hydraxylase Deficiency   CYP21A2   AR   Reduced Risk     Congental Adrenat Hyperplasia due to 27-Hydraxylase   CYP21A2   AR   Reduced Risk     Congental Adrenat Hyperplasia due to 27-Hydraxylase   CYP21A2   AR   Reduced Risk     Congental Adrenat Hyperplasia due to 27-Hydraxylase   CYP21A2   AR   Reduced Risk     Congental Mediative Phosphorylation Type I   MPL   AR   Reduced Risk     Congental Mediative Phosphorylation Type I   MPL   AR   Reduced Risk     Congental Mediative Phosphorylation Type I   ALG6   AR   Reduced Risk     Congental Mystheric Syndrome (CMANE-Related)   PAFSN	Cohen Syndrome	VPS13B	AR	Reduced Risk	
Combined Oxidative Phosphorylation Deficiency 3   TSFM   AR   Reduced Risk     Combined Pluitary Homone Deficiency 3   LHX3   AR   Reduced Risk     Combined Pluitary Homone Deficiency 3   LHX3   AR   Reduced Risk     Combined SAP Deficiency   PSAP   AR   Reduced Risk     Congenital Adrenal Hyperplasia due to 17-Alpha- Hydroxylase Deficiency   CYP21A2   AR   Reduced Risk     Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency   CYP21A2   AR   Reduced Risk     Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency   CYP21A2   AR   Reduced Risk     Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency   CYP21A2   AR   Reduced Risk     Congenital Disorder of Glycoxylation Type Ia   MPL   AR   Reduced Risk     Congenital Insensitivity to Pain with Arhidrosis   MTR4   AR   Reduced Risk     Congenital Insensitivity to Pain with Arhidrosis   MTR4   AR   Reduced Risk     Congenital Mysshenic Syndrome (CHRNE-Related)   CHRNE   AR   Reduced Risk     Congenital Neutropenia (MAX-Related)   HAX1   AR   Reduced Risk     Congenital Neutropenia (MAX-Related)   HAX1	Combined Malonic and Methylmalonic Aciduria	ACSF3	AR	Reduced Risk	
Combined Pitultary Homone Deficiency 2   PROP1   AR   Reduced Risk     Combined Pitultary Homone Deficiency 3   LHX3   AR   Reduced Risk     Compental Adrenal Hyperplasia due to 17-Alpine- Mydroxylase Deficiency   CYP21A2   AR   Reduced Risk     Congential Adrenal Hyperplasia due to 21-Hydroxylase Deficiency   CYP21A2   AR   Reduced Risk     Congential Adrenal Hyperplasia due to 21-Hydroxylase Deficiency   CYP21A2   AR   Reduced Risk     Congential Adrenal Hyperplasia due to 21-Hydroxylase Deficiency   CYP21A2   AR   Reduced Risk     Congential Adrenal Hyperplasia due to 21-Hydroxylase Deficiency   CYP21A2   AR   Reduced Risk     Congential Amegakarycoydc Thrombocytopenia   MPL   AR   Reduced Risk     Congential Disorder of Glycoxylation, Type Ib   MPL   AR   Reduced Risk     Congential Insensitivity to Pain with Anhidrosis   NTR/a   AR   Reduced Risk     Congential Myasthenic Syndrome ( <i>HAPSN</i> -Related)   CHRNE   AR   Reduced Risk     Congential Neutropenia ( <i>HAX</i> : Related)   HAX1   AR   Reduced Risk     Congential Neutropenia ( <i>HAX</i> : Related)   HAX1   AR   Reduced Risk     Congential Neutropenia ( <i>HA</i>	Combined Oxidative Phosphorylation Deficiency 1	GFM1	AR	Reduced Risk	
Combined Pituitary Homone Deficiency 3   LHX3   AR   Reduced Risk     Combined SAP Deficiency   PSAP   AR   Reduced Risk     Congenital Adrenal Hyperplasia due to 17-Alpha- Hydroxylase Deficiency   CVP21A2   AR   Reduced Risk     Congenital Adrenal Hyperplasia due to 21-Hydroxylase   CVP21A2   AR   Reduced Risk   CVP21A2 sequencing: Negative     Congenital Adrenal Hyperplasia due to 21-Hydroxylase   CVP21A2   AR   Reduced Risk   CVP21A2 sequencing: Negative     Congenital Amegakaryoxyld: Thromboxylopenia   MPL   AR   Reduced Risk   Congenital Disorder of Glycoxylation, Type Ia     Congenital Disorder of Glycoxylation, Type Ia   PMM2   AR   Reduced Risk   Congenital Disorder of Glycoxylation, Type Ia     Congenital Disorder of Glycoxylation, Type Ia   PMM2   AR   Reduced Risk   Congenital Myasthenic Syndrome (CHRNE-Feelated)   CHRNE   AR   Reduced Risk   Congenital Myasthenic Syndrome (CHRNE-Feelated)   CHRNE   AR   Reduced Risk   Congenital Myasthenic Syndrome (CHAPSN-Related)   RAPSN   AR   Reduced Risk   Congenital Myasthenic Syndrome (CHAPSN-Related)   PAS4/5   AR   Reduced Risk   Congenital Neutropenia (VPS4/5-Related)   VPS4/5   AR   Reduced Risk	Combined Oxidative Phosphorylation Deficiency 3	TSFM	AR	Reduced Risk	
Combined SAP Deficiency     PSAP     AR     Reduced Risk       Congenital Adrenal Hyperplasia due to 17-Alpha- Mydroxylase Dinfeiency     CVP17A1     AR     Reduced Risk     CVP21A2 copy number: 2 CVP21A2 copy number: 2 CVP21A2 sequencing: Negative       Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency     CVP21A2     AR     Reduced Risk     CVP21A2 copy number: 2 CVP21A2 sequencing: Negative       Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency     CVP21A2     AR     Reduced Risk     CVP21A2 copy number: 2 CVP21A2 sequencing: Negative       Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency     CVP21A2     AR     Reduced Risk     CVP21A2 copy number: 2 CVP21A2 sequencing: Negative       Congenital Disorder of Glycosylation. Type Ia     MPL     AR     Reduced Risk     Congenital Disorder of Glycosylation. Type Ib     MPI     AR     Reduced Risk       Congenital Inserstivity to Pain with Anhidrosis     NTRK1     AR     Reduced Risk     Congenital Myssheric Syndrome (CHRNE-Related)     CHRNE     AR     Reduced Risk       Congenital Neutropenia (HAX2-Related)     HAX1     AR     Reduced Risk     Congenital Neutropenia (HAX2-Related)     VP545     AR     Reduced Risk     Congenital Neutropenia (HAX2-Related)	Combined Pituitary Hormone Deficiency 2	PROP1	AR	Reduced Risk	
Congenital Adrenal Hyperplasia due to 17-Alpha- Hydroxylase Deficiency   CYP17A1   AR   Reduced Risk     Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency   CYP21A2   AR   Reduced Risk   CYP21A2 copy number: 2 CYP21A2 sequencing: Negative     Congenital Amegakaryocytic Thrombocytopenia   MPL   AR   Reduced Risk   CYP21A2 sequencing: Negative     Congenital Disorder of Glycosylation, Type Ia   PMM2   AR   Reduced Risk   Congenital Disorder of Glycosylation, Type Ib     Congenital Disorder of Glycosylation, Type Ib   MPI   AR   Reduced Risk   Congenital Disorder of Glycosylation, Type Ib     Congenital Insensitivity to Pain with Anhidrosis   NTRK1   AR   Reduced Risk   Congenital Mysstheric Syndrome (CHRNE-Related)   CHRNE   AR   Reduced Risk   Congenital Neutropenia (HAX2-Related)   CHRNE   AR   Reduced Risk   Congenital Neutropenia (HAX2-Related)   HAX1   AR   Reduced Risk   Congenital Neutropenia (HAX2-Related)   HAX1   AR   Reduced Risk   Congenital Neutropenia (HAX2-Related)   HAX1   AR   Reduced Risk   Congenital Neutropenia (HAX2-Related)   HAX2   AR   Reduced Risk   Congenital Neutropenia (HAX2-Related)   HAX1   AR   Reduced Risk   Congenital Neutropenia (HAX2-Rel	Combined Pituitary Hormone Deficiency 3	LHX3	AR	Reduced Risk	
Hydraxylase Deficiency CHP2/AL AR Reduced Risk   Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency CYP21A2 AR Reduced Risk CYP21A2 copy number: 2 CYP21A2 sequencing: Negative   Congenital Amegakarycoytic Thrombocytopenia MPL AR Reduced Risk CYP21A2 sequencing: Negative   Congenital Disorder of Glycosylation, Type Ia MPL AR Reduced Risk Congenital Disorder of Glycosylation, Type Ib   Congenital Disorder of Glycosylation, Type Ib MPI AR Reduced Risk   Congenital Disorder of Glycosylation, Type Ib MIPI AR Reduced Risk   Congenital Insensitivity to Pain with Anhidrosis NTRK1 AR Reduced Risk   Congenital Myasthenic Syndrome (CHRNE-Related) CHRNE AR Reduced Risk   Congenital Nyasthenic Syndrome (CHRNE-Related) FAPSN AR Reduced Risk   Congenital Neutropenia (HAX4-Related) HAX1 AR Reduced Risk   Congenital Neutropenia (HPS4G-Related) VPS45 AR Reduced Risk   Cotricosterone	Combined SAP Deficiency	PSAP	AR	Reduced Risk	
Deficiency AR Reduced Risk CYP21A2 sequencing: Negative   Congenital Amegakaryocytic Thrombocytopenia MPL AR Reduced Risk   Congenital Disorder of Glycosylation, Type Ia PMM2 AR Reduced Risk   Congenital Disorder of Glycosylation, Type Ia MPL AR Reduced Risk   Congenital Disorder of Glycosylation, Type Ia MPL AR Reduced Risk   Congenital Disorder of Glycosylation, Type Ib MPL AR Reduced Risk   Congenital Insertivity to Pain with Anhidrosis NTRK1 AR Reduced Risk   Congenital Myasthenic Syndrome (CHRNE-Related) CHRNE AR Reduced Risk   Congenital Neutropenia (HAV3-Related) CHRNE AR Reduced Risk   Congenital Neutropenia (HAV3-Related) HAX1 AR Reduced Risk   Congenital Neutropenia (HAV3-Related) VPS45 AR Reduced Risk   Congenital Neutropenia (VPS45-Related) VPS45 AR Reduced Risk   Conference Creftre AR Reduced Risk		CYP17A1	AR	Reduced Risk	
Congenital Disorder of Glycosylation, Type Ia   PMM2   AR   Reduced Risk     Congenital Disorder of Glycosylation, Type Ib   MPI   AR   Reduced Risk     Congenital Disorder of Glycosylation, Type Ic   ALG6   AR   Reduced Risk     Congenital Insensitivity to Pain with Anhidrosis   NTRK1   AR   Reduced Risk     Congenital Insensitivity to Pain with Anhidrosis   NTRK1   AR   Reduced Risk     Congenital Myasthenic Syndrome (CHRNE-Related)   CHRNE   AR   Reduced Risk     Congenital Neutropenia (HAX1-Related)   RAVSN   AR   Reduced Risk     Congenital Neutropenia (VPS45-Related)   HAX1   AR   Reduced Risk     Congenital Neutropenia (VPS45-Related)   VPS45   AR   Reduced Risk     Congenital Neutropenia (VPS45-Related)   VPS45   AR   Reduced Risk     Cordicosterone Methyloxidase Deficiency   CYP11B2   AR   Reduced Risk     Cystinosis   CTNS   AR   Reduced Risk     Cystinosis   CTNS   AR   Reduced Risk     Delfrenctional Protein Deficiency   HSD17B4   AR   Reduced Risk     Deefrees Autosomal Recessive 77   LOXHD1   A		CYP21A2	AR	Reduced Risk	
Congenital Disorder of Glycosylation, Type IbMPIARReduced RiskCongenital Disorder of Glycosylation, Type IcALG6ARReduced RiskCongenital Insensitivity to Pain with AnhidrosisNTRk1ARReduced RiskCongenital Myasthenic Syndrome (CHRNE-Related)CHRNEARReduced RiskCongenital Myasthenic Syndrome (RAPSN+Related)RAPSNARReduced RiskCongenital Neutropenia (HAX2-Related)HAX1ARReduced RiskCongenital Neutropenia (VPS45-Related)VPS45ARReduced RiskConference Neutropenia (VPS45-Related)CrTrrsARReduced RiskConference Neutropenia (VPS45-Related)VPS45ARReduced RiskDeafness, Autosomal Recessive 77LOXHD1	Congenital Amegakaryocytic Thrombocytopenia	MPL	AR	Reduced Risk	
Congenital Disorder of Glycosylation, Type Ic   ALG6   AR   Reduced Risk     Congenital Insensitivity to Pain with Anhidrosis   NTRK1   AR   Reduced Risk     Congenital Myasthenic Syndrome (CHRNE-Related)   CHRNE   AR   Reduced Risk     Congenital Myasthenic Syndrome (RAPSN-Related)   CHRNE   AR   Reduced Risk     Congenital Neutropenia (HAX2-Related)   HAX1   AR   Reduced Risk     Congenital Neutropenia (VPS46-Related)   VPS45   AR   Reduced Risk     Congenital Neutropenia (VPS46-Related)   VPS45   AR   Reduced Risk     Cordicosterone Methyloxidase Deficiency   CYP11B2   AR   Reduced Risk     Cystic Fibrosis   CTNS   AR   Reduced Risk     Cystic rolicosis   CTNS   AR   Reduced Risk     Definencional Protein Deficiency   HSD17B4   AR   Reduced Risk     Definence Muscular Dystrophy / Becker Muscular   DMD <t< th=""><th>Congenital Disorder of Glycosylation, Type la</th><th>PMM2</th><th>AR</th><th>Reduced Risk</th><th></th></t<>	Congenital Disorder of Glycosylation, Type la	PMM2	AR	Reduced Risk	
Congenital Insensitivity to Pain with Anhidrosis   NTRK1   AR   Reduced Risk     Congenital Myasthenic Syndrome (CHRNE-Related)   CHRNE   AR   Reduced Risk     Congenital Myasthenic Syndrome (RAPSN-Related)   RAPSN   AR   Reduced Risk     Congenital Neutropenia (HAX1-Related)   HAX1   AR   Reduced Risk     Congenital Neutropenia (VPS45-Related)   HAX1   AR   Reduced Risk     Congenital Neutropenia (VPS45-Related)   VPS45   AR   Reduced Risk     Congenital Neutropenia (VPS46-Related)   CYP11B2   AR   Reduced Risk     Cystinosis   CFTR   AR   Reduced Risk   Political Protein Deficiency     HSD17B4	Congenital Disorder of Glycosylation, Type Ib	MPI	AR	Reduced Risk	
Congenital Myasthenic Syndrome (CHRINE-Related)   CHRINE   AR   Reduced Risk     Congenital Myasthenic Syndrome (RAPSN-Related)   RAPSN   AR   Reduced Risk     Congenital Neutropenia (HAX1-Related)   HAX1   AR   Reduced Risk     Congenital Neutropenia (HAX1-Related)   HAX1   AR   Reduced Risk     Congenital Neutropenia (VPS45-Related)   VPS45   AR   Reduced Risk     Congenital Neutropenia (VPS45-Related)   VPS45   AR   Reduced Risk     Corneal Dystrophy and Perceptive Deafness   SLC4A11   AR   Reduced Risk     Corticosterone Methyloxidase Deficiency   CYP11B2   AR   Reduced Risk     Cystic Fibrosis   CFTR   AR   Reduced Risk     Cystinosis   CTNS   AR   Reduced Risk     Delifunctional Protein Deficiency   HSD17B4   AR   Reduced Risk     Deafness, Autosomal Recessive 77   LOXHD1   AR   Reduced Risk     Duchenne Muscular Dystrophy / Becker Muscular   DMD   XL   Reduced Risk	Congenital Disorder of Glycosylation, Type Ic	ALG6	AR	Reduced Risk	
Congenital Myasthenic Syndrome (RAPSN-Related)   RAPSN   AR   Reduced Risk     Congenital Neutropenia (HAX1-Related)   HAX1   AR   Reduced Risk     Congenital Neutropenia (WPS4g-Related)   VPS4g   AR   Reduced Risk     Congenital Neutropenia (WPS4g-Related)   VPS4g   AR   Reduced Risk     Congenital Neutropenia (WPS4g-Related)   VPS4g   AR   Reduced Risk     Corneal Dystrophy and Perceptive Deafness   SLC4A11   AR   Reduced Risk     Corticosterone Methyloxidase Deficiency   CVP11B2   AR   Reduced Risk     Cystic Fibrosis   CFTR   AR   Reduced Risk     Cystinosis   CTNS   AR   Reduced Risk     Delifunctional Protein Deficiency   HSD17B4   AR   Reduced Risk     Deafness, Autosomal Recessive 77   LOXHD1   AR   Reduced Risk     Duchenne Muscular Dystrophy / Becker Muscular   DMD   XL   Reduced Risk	Congenital Insensitivity to Pain with Anhidrosis	NTRK1	AR	Reduced Risk	
Congenital Neutropenia ( <i>HAX1</i> -Related)HAX1ARReduced RiskCongenital Neutropenia ( <i>VPS45</i> -Related)VP545ARReduced RiskCorneal Dystrophy and Perceptive DeafnessSLC4A11ARReduced RiskCorticosterone Methyloxidase DeficiencyCYP11B2ARReduced RiskCystic FibrosisCFTRARReduced RiskCystinosisCTNSARReduced RiskDeficiencyHSD17B4ARReduced RiskDeafness, Autosomal Recessive 77LOXHD1ARReduced RiskDuchenne Muscular Dystrophy / Becker Muscular DystrophyDMDXLReduced Risk	Congenital Myasthenic Syndrome (CHRNE-Related)	CHRNE	AR	Reduced Risk	
Congenital Neutropenia (VPS45-Related)   VPS45   AR   Reduced Risk     Corneal Dystrophy and Perceptive Deafness   SLC4A11   AR   Reduced Risk     Corticosterone Methylaxidase Deficiency   CYP11B2   AR   Reduced Risk     Cystic Fibrosis   CFTR   AR   Reduced Risk     Cystinosis   CTNS   AR   Reduced Risk     Deafness, Autosomal Recessive 77   LOXHD1   AR   Reduced Risk     Duchenne Muscular Dystrophy / Becker Muscular   DMD   XL   Reduced Risk	Congenital Myasthenic Syndrome (RAPSN-Related)	RAPSN	AR	Reduced Risk	
Corneal Dystrophy and Perceptive Deafness   SLC4A11   AR   Reduced Risk     Corticosterone Methyloxidase Deficiency   CYP11B2   AR   Reduced Risk     Cystic Fibrosis   CFTR   AR   Reduced Risk     Cystinosis   CTNS   AR   Reduced Risk     D-Bifunctional Protein Deficiency   HSD17B4   AR   Reduced Risk     Deafness, Autosomal Recessive 77   LOXHD1   AR   Reduced Risk     Duchenne Muscular Dystrophy / Becker Muscular   DMD   XL   Reduced Risk	Congenital Neutropenia (HAX1-Related)	HAX1	AR	Reduced Risk	
Corticosterone Methyloxidase DeficiencyCYP11B2ARReduced RiskCystic FibrosisCFTRARReduced RiskCystinosisCTNSARReduced RiskD-Bifunctional Protein DeficiencyHSD17B4ARReduced RiskDeafness, Autosomal Recessive 77LOXHD1ARReduced RiskDuchenne Muscular Dystrophy / Becker MuscularDMDXLReduced Risk	Congenital Neutropenia (VPS45-Related)	VPS45	AR	Reduced Risk	
Cystic FibrosisCFTRARReduced RiskCystinosisCTNSARReduced RiskD-Bifunctional Protein DeficiencyHSD17B4ARReduced RiskDeafness, Autosomal Recessive 77LOXHD1ARReduced RiskDuchenne Muscular Dystrophy / Becker MuscularDMDXLReduced Risk	Corneal Dystrophy and Perceptive Deafness	SLC4A11	AR	Reduced Risk	
Cystinosis   CTNS   AR   Reduced Risk     D-Bifunctional Protein Deficiency   HSD17B4   AR   Reduced Risk     Deafness, Autosomal Recessive 77   LOXHD1   AR   Reduced Risk     Duchenne Muscular Dystrophy / Becker Muscular Dystrophy   DMD   XL   Reduced Risk	Corticosterone Methyloxidase Deficiency	CYP11B2	AR	Reduced Risk	
D-Bifunctional Protein Deficiency   HSD17B4   AR   Reduced Risk     Deafness, Autosomal Recessive 77   LOXHD1   AR   Reduced Risk     Duchenne Muscular Dystrophy / Becker Muscular   DMD   XL   Reduced Risk	Cystic Fibrosis	CFTR	AR	Reduced Risk	
Deafness, Autosomal Recessive 77 LOXHD1 AR Reduced Risk   Duchenne Muscular Dystrophy / Becker Muscular DMD XL Reduced Risk	Cystinosis	CTNS	AR	Reduced Risk	
Duchenne Muscular Dystrophy / Becker Muscular DMD XL Reduced Risk	D-Bifunctional Protein Deficiency	HSD17B4	AR	Reduced Risk	
Dystrophy DMD XL Reduced Risk	Deafness, Autosomal Recessive 77	LOXHD1	AR	Reduced Risk	
Dyskeratosis Congenita (RTEL1-Related) RTEL1 AR Reduced Risk		DMD	XL	Reduced Risk	
	Dyskeratosis Congenita ( <i>RTEL1</i> -Related)	RTEL1	AR	Reduced Risk	

CLIA # 33D2097541 T: 800-298-6470 F: 212-241-0139 www.sema4.com





Dystrophic Epidermolysis Bullosa	COL7A1	AR	Reduced Risk	
Ehlers-Danlos Syndrome, Type VIIC	ADAMTS2	AR	Reduced Risk	
Ellis-van Creveld Syndrome (EVC-Related)	EVC	AR	Reduced Risk	
Emery-Dreifuss Myopathy 1	EMD	XL	Reduced Risk	
Enhanced S-Cone Syndrome	NR2E3	AR	Reduced Risk	
Ethylmalonic Encephalopathy	ETHE1	AR	Reduced Risk	
Fabry Disease	GLA	XL	Reduced Risk	
Factor IX Deficiency	F9	XL	Reduced Risk	
Factor XI Deficiency	F11	AR	Reduced Risk	
Familial Autosomal Recessive Hypercholesterolemia	LDLRAP1	AR	Reduced Risk	
Familial Dysautonomia	IKBKAP	AR	Reduced Risk	
Familial Hypercholesterolemia	LDLR	AR	Reduced Risk	
Familial Hyperinsulinism (ABCC8-Related)	ABCC8	AR	Reduced Risk	
Familial Hyperinsulinism (KCNJ11-Related)	KCNJ11	AR	Reduced Risk	
Familial Mediterranean Fever	MEFV	AR	Reduced Risk	
Fanconi Anemia, Group A	FANCA	AR	Reduced Risk	
Fanconi Anemia, Group C	FANCC	AR	Reduced Risk	
Fanconi Anemia, Group G	FANCG	AR	Reduced Risk	
Fragile X Syndrome	FMR1	XL	Reduced Risk	FMR1 CGG repeat sizes: Not Performed FMR1 Sequencing: Negative Fragile X CGG triplet repeat expansion testing was not performed at this time, as the patient has eithe been previously tested or is a male.
Fumarase Deficiency	FH	AR	Reduced Risk	
GRACILE Syndrome and Other BCS1L-Related Disorders	BCS1L	AR	Reduced Risk	
Galactokinase Deficiency	GALK1	AR	Reduced Risk	
Galactosemia	GALT	AR	Reduced Risk	
Gaucher Disease	GBA	AR	Reduced Risk	
Gitelman Syndrome	SLC12A3	AR	Reduced Risk	
Glutaric Acidemia, Type I	GCDH	AR	Reduced Risk	
Glutaric Acidemia, Type IIa	ETFA	AR	Reduced Risk	
Glutaric Acidemia, Type IIc	ETFDH	AR	Reduced Risk	
Glycine Encephalopathy (AMT-Related)	AMT	AR	Reduced Risk	
Glycine Encephalopathy (GLDC-Related)	GLDC	AR	Reduced Risk	
Glycogen Storage Disease, Type II	GAA	AR	Reduced Risk	
Glycogen Storage Disease, Type III	AGL	AR	Reduced Risk	
Glycogen Storage Disease, Type IV / Adult Polyglucosan Body Disease	GBE1	AR	Reduced Risk	





Glycogen Storage Disease, Type Ia	G6PC	AR	Reduced Risk
Glycogen Storage Disease, Type Ib	SLC37A4	AR	Reduced Risk
Glycogen Storage Disease, Type V	PYGM	AR	Reduced Risk
Glycogen Storage Disease, Type VII	PFKM	AR	Reduced Risk
HMG-CoA Lyase Deficiency	HMGCL	AR	Reduced Risk
Hemochromatosis, Type 2A	HFE2	AR	Reduced Risk
Hemochromatosis, Type 3	TFR2	AR	Reduced Risk
Hereditary Fructose Intolerance	ALDOB	AR	Reduced Risk
Hereditary Spastic Paraparesis 49	TECPR2	AR	Reduced Risk
Hermansky-Pudlak Syndrome, Type 1	HPS1	AR	Reduced Risk
Hermansky-Pudlak Syndrome, Type 3	HPS3	AR	Reduced Risk
Holocarboxylase Synthetase Deficiency	HLCS	AR	Reduced Risk
Homocystinuria (CBS-Related)	CBS	AR	Reduced Risk
Homocystinuria due to MTHFR Deficiency	MTHFR	AR	Reduced Risk
Homocystinuria, cblE Type	MTRR	AR	Reduced Risk
Hydrolethalus Syndrome	HYLS1	AR	Reduced Risk
Hyperomithinemia-Hyperammonemia-Homocitrullinuria Syndrome	SLC25A15	AR	Reduced Risk
Hypohidrotic Ectodermal Dysplasia 1	EDA	XL	Reduced Risk
Hypophosphatasia	ALPL	AR	Reduced Risk
Inclusion Body Myopathy 2	GNE	AR	Reduced Risk
Infantile Cerebral and Cerebellar Atrophy	MED17	AR	Reduced Risk
Isovaleric Acidemia	IVD	AR	Reduced Risk
Joubert Syndrome 2	TMEM216	AR	Reduced Risk
Joubert Syndrome 7 / Meckel Syndrome 5 / COACH Syndrome	RPGRIP1L	AR	Reduced Risk
Junctional Epidermolysis Bullosa (LAMA3-Related)	LAMA3	AR	Reduced Risk
Junctional Epidermolysis Bullosa (LAMB3-Related)	LAMB3	AR	Reduced Risk
Junctional Epidermolysis Bullosa (LAMC2-Related)	LAMC2	AR	Reduced Risk
Krabbe Disease	GALC	AR	Reduced Risk
Lamellar Ichthyosis, Type 1	TGM1	AR	Reduced Risk
Leber Congenital Amaurosis 10 and Other CEP290- Related Ciliopathies	CEP290	AR	Reduced Risk
Leber Congenital Amaurosis 13	RDH12	AR	Reduced Risk
Leber Congenital Amaurosis 2 / Retinitis Pigmentosa 20	RPE65	AR	Reduced Risk
Leber Congenital Amaurosis 5	LCA5	AR	Reduced Risk
Leber Congenital Amaurosis 8 / Retinitis Pigmentosa 12 / Pigmented Paravenous Chorioretinal Atrophy	CRB1	AR	Reduced Risk

CLIA # 33D2097541 T: 800-298-6470 F: 212-241-0139 www.sema4.com





Leigh Syndrome, French-Canadian Type	LRPPRC	AR	Reduced Risk
Lethal Congenital Contracture Syndrome 1 / Lethal Arthrogryposis with Anterior Horn Cell Disease	GLE1	AR	Reduced Risk
Leukoencephalopathy with Vanishing White Matter	EIF2B5	AR	Reduced Risk
Limb-Girdle Muscular Dystrophy, Type 2A	CAPN3	AR	Reduced Risk
Limb-Girdle Muscular Dystrophy, Type 2B	DYSF	AR	Reduced Risk
Limb-Girdle Muscular Dystrophy, Type 2C	SGCG	AR	Reduced Risk
Limb-Girdle Muscular Dystrophy, Type 2D	SGCA	AR	Reduced Risk
Limb-Girdle Muscular Dystrophy, Type 2E	SGCB	AR	Reduced Risk
Limb-Girdle Muscular Dystrophy, Type 21	FKRP	AR	Reduced Risk
Lipoamide Dehydrogenase Deficiency	DLD	AR	Reduced Risk
Lipoid Adrenal Hyperplasia	STAR	AR	Reduced Risk
Lipoprotein Lipase Deficiency	LPL	AR	Reduced Risk
Long-Chain 3-Hydroxyacyl-CoA Dehydrogenase Deficiency	HADHA	AR	Reduced Risk
Lysinuric Protein Intolerance	SLC7A7	AR	Reduced Risk
Maple Syrup Urine Disease, Type 1a	BCKDHA	AR	Reduced Risk
Maple Syrup Urine Disease, Type 1b	BCKDHB	AR	Reduced Risk
Meckel 1 / Bardet-Biedl Syndrome 13	MKS1	AR	Reduced Risk
Medium Chain Acyl-CoA Dehydrogenase Deficiency	ACADM	AR	Reduced Risk
Megalencephalic Leukoencephalopathy with Subcortical Cysts	MLC1	AR	Reduced Risk
Menkes Disease	ATP7A	XL	Reduced Risk
Metachromatic Leukodystrophy	ARSA	AR	Reduced Risk
Methylmalonic Acidemia (MMAA-Related)	MMAA	AR	Reduced Risk
Methylmalonic Acidemia (MMAB-Related)	MMAB	AR	Reduced Risk
Methylmalonic Acidemia (MUT-Related)	MUT	AR	Reduced Risk
Methylmalonic Aciduria and Homocystinuria, Cobalamin C Type	MMACHC	AR	Reduced Risk
Methylmalonic Aciduria and Homocystinuria, Cobalamin D Type	MMADHC	AR	Reduced Risk
Microphthalmia / Anophthalmia	VSX2	AR	Reduced Risk
Mitochondrial Complex I Deficiency (ACADg-Related)	ACAD9	AR	Reduced Risk
Mitochondrial Complex I Deficiency (NDUFAF5-Related)	NDUFAF5	AR	Reduced Risk
Mitochondrial Complex I Deficiency (NDUFS6-Related)	NDUFS6	AR	Reduced Risk
Mitochondrial DNA Depletion Syndrome 6 / Navajo Neurohepatopathy	MPV17	AR	Reduced Risk
Mitochondrial Myopathy and Sideroblastic Anemia 1	PUS1	AR	Reduced Risk

CLIA # 33D2097541 T: 800-298-6470 F: 212-241-0139 www.sema4.com





Mucolipidosis II / IIIA	GNPTAB	AR	Reduced Risk
Mucolipidosis III Gamma	GNPTG	AR	Reduced Risk
Mucolipidosis IV	MCOLN1	AR	Reduced Risk
Mucopolysaccharidosis Type I	IDUA	AR	Reduced Risk
Mucopolysaccharidosis Type II	IDS	XL	Reduced Risk
Mucopolysaccharidosis Type IIIA	SGSH	AR	Reduced Risk
Mucopolysaccharidosis Type IIIB	NAGLU	AR	Reduced Risk
Mucopolysaccharidosis Type IIIC	HGSNAT	AR	Reduced Risk
Mucopolysaccharidosis Type IIID	GNS	AR	Reduced Risk
Mucopolysaccharidosis Type IVb / GM1 Gangliosidosis	GLB1	AR	Reduced Risk
Mucopolysaccharidosis type IX	HYAL1	AR	Reduced Risk
Mucopolysaccharidosis type VI	ARSB	AR	Reduced Risk
Multiple Sulfatase Deficiency	SUMF1	AR	Reduced Risk
Muscle-Eye-Brain Disease and Other <i>POMGNT1</i> -Related Congenital Muscular Dystrophy-Dystroglycanopathies	POMGNT1	AR	Reduced Risk
Myoneurogastrointestinal Encephalopathy	TYMP	AR	Reduced Risk
Myotubular Myopathy 1	MTM1	XL	Reduced Risk
N-Acetylglutamate Synthase Deficiency	NAGS	AR	Reduced Risk
Nemaline Myopathy 2	NEB	AR	Reduced Risk
Nephrogenic Diabetes Insipidus, Type II	AQP2	AR	Reduced Risk
Nephrotic Syndrome ( <i>NPHS1</i> -Related) / Congenital Finnish Nephrosis	NPHS1	AR	Reduced Risk
Nephrotic Syndrome ( <i>NPHS2</i> -Related) / Steroid- Resistant Nephrotic Syndrome	NPHS2	AR	Reduced Risk
Neuronal Ceroid-Lipofuscinosis (CLN3-Related)	CLN3	AR	Reduced Risk
Neuronal Ceroid-Lipofuscinosis (CLN5-Related)	CLN5	AR	Reduced Risk
Neuronal Ceroid-Lipofuscinosis (CLN6-Related)	CLN6	AR	Reduced Risk
Neuronal Ceroid-Lipofuscinosis (CLN8-Related)	CLN8	AR	Reduced Risk
Neuronal Ceroid-Lipofuscinosis (MFSD8-Related)	MFSD8	AR	Reduced Risk
Neuronal Ceroid-Lipofuscinosis (PPT1-Related)	PPT1	AR	Reduced Risk
Neuronal Ceroid-Lipofuscinosis (TPP1-Related)	TPP1	AR	Reduced Risk
Niemann-Pick Disease (SMPD1-Related)	SMPD1	AR	Reduced Risk
Niemann-Pick Disease, Type C ( <i>NPC1</i> -Related)	NPC1	AR	Reduced Risk
Niemann-Pick Disease, Type C ( <i>NPC2</i> -Related)	NPC2	AR	Reduced Risk
Nijmegen Breakage Syndrome	NBN	AR	Reduced Risk
Non-Syndromic Hearing Loss (GJB2-Related)	GJB2	AR	Reduced Risk
Odonto-Onycho-Dermal Dysplasia / Schopf-Schulz- Passarge Syndrome	WNT10A	AR	Reduced Risk





Omenn Syndrome ( <i>RAG2</i> -Related)	RAG2	AR	Reduced Risk
Omenn Syndrome / Severe Combined Immunodeficiency, Athabaskan-Type	DCLRE1C	AR	Reduced Risk
Ornithine Aminotransferase Deficiency	OAT	AR	Reduced Risk
Ornithine Transcarbamylase Deficiency	OTC	XL	Reduced Risk
Osteopetrosis 1	TCIRG1	AR	Reduced Risk
Pendred Syndrome	SLC26A4	AR	Reduced Risk
Phenylalanine Hydroxylase Deficiency	PAH	AR	Reduced Risk
Polycystic Kidney Disease, Autosomal Recessive	PKHD1	AR	Reduced Risk
Polyglandular Autoimmune Syndrome, Type 1	AIRE	AR	Reduced Risk
Pontocerebellar Hypoplasia, Type 1A	VRK1	AR	Reduced Risk
Pontocerebellar Hypoplasia, Type 6	RARS2	AR	Reduced Risk
Primary Carnitine Deficiency	SLC22A5	AR	Reduced Risk
Primary Ciliary Dyskinesia (DNAH5-Related)	DNAH5	AR	Reduced Risk
Primary Ciliary Dyskinesia (DNA/1-Related)	DNAI1	AR	Reduced Risk
Primary Ciliary Dyskinesia (DNA/2-Related)	DNAI2	AR	Reduced Risk
Primary Hyperoxaluria, Type 1	AGXT	AR	Reduced Risk
Primary Hyperoxaluria, Type 2	GRHPR	AR	Reduced Risk
Primary Hyperoxaluria, Type 3	HOGA1	AR	Reduced Risk
Progressive Cerebello-Cerebral Atrophy	SEPSECS	AR	Reduced Risk
Progressive Familial Intrahepatic Cholestasis, Type 2	ABCB11	AR	Reduced Risk
Propionic Acidemia (PCCA-Related)	PCCA	AR	Reduced Risk
Propionic Acidemia (PCCB-Related)	PCCB	AR	Reduced Risk
Pycnodysostosis	CTSK	AR	Reduced Risk
Pyruvate Dehydrogenase E1-Alpha Deficiency	PDHA1	XL	Reduced Risk
Pyruvate Dehydrogenase E1-Beta Deficiency	PDHB	AR	Reduced Risk
Renal Tubular Acidosis and Deafness	ATP6V1B1	AR	Reduced Risk
Retinitis Pigmentosa 25	EYS	AR	Reduced Risk
Retinitis Pigmentosa 26	CERKL	AR	Reduced Risk
Retinitis Pigmentosa 28	FAM161A	AR	Reduced Risk
Retinitis Pigmentosa 59	DHDDS	AR	Reduced Risk
Rhizomelic Chondrodysplasia Punctata, Type 1	PEX7	AR	Reduced Risk
Rhizomelic Chondrodysplasia Punctata, Type 3	AGPS	AR	Reduced Risk
Roberts Syndrome	ESCO2	AR	Reduced Risk
Salla Disease	SLC17A5	AR	Reduced Risk
SandhoffDisease	HEXB	AR	Reduced Risk





Schimke Immunoosseous Dysplasia	SMARCAL1	AR	Reduced Risk
Segawa Syndrome	ТН	AR	Reduced Risk
Sjogren-Larsson Syndrome	ALDH3A2	AR	Reduced Risk
Smith-Lemli-Opitz Syndrome	DHCR7	AR	Reduced Risk
Spondylothoracic Dysostosis	MESP2	AR	Reduced Risk
Steel Syndrome	COL27A1	AR	Reduced Risk
Stuve-Wiedemann Syndrome	LIFR	AR	Reduced Risk
Sulfate Transporter-Related Osteochondrodysplasia	SLC26A2	AR	Reduced Risk
Tay-Sachs Disease	HEXA	AR	Reduced Risk
Tyrosinemia, Type I	FAH	AR	Reduced Risk
Usher Syndrome, Type IB	ΜΥΟ7Α	AR	Reduced Risk
Usher Syndrome, Type IC	USH1C	AR	Reduced Risk
Usher Syndrome, Type ID	CDH23	AR	Reduced Risk
Usher Syndrome, Type IF	PCDH15	AR	Reduced Risk
Usher Syndrome, Type IIA	USH2A	AR	Reduced Risk
Usher Syndrome, Type III	CLRN1	AR	Reduced Risk
Very Long Chain Acyl-CoA Dehydrogenase Deficiency	ACADVL	AR	Reduced Risk
Walker-Warburg Syndrome and Other FKTN-Related Dystrophies	FKTN	AR	Reduced Risk
Wilson Disease	ATP7B	AR	Reduced Risk
Wolman Disease / Cholesteryl Ester Storage Disease	LIPA	AR	Reduced Risk
X-Linked Juvenile Retinoschisis	RS1	XL	Reduced Risk
X-Linked Severe Combined Immunodeficiency	IL2RG	XL	Reduced Risk
Zellweger Syndrome Spectrum (PEX10-Related)	PEX10	AR	Reduced Risk
Zellweger Syndrome Spectrum (PEX1-Related)	PEX1	AR	Reduced Risk
Zellweger Syndrome Spectrum (PEX2-Related)	PEX2	AR	Reduced Risk
Zellweger Syndrome Spectrum (PEX6-Related)	PEX6	AR	Reduced Risk

AR=Autosomal recessive; XL=X-linked

# Test methods and comments

Genomic DNA isolated from this patient was analyzed by one or more of the following methodologies, as applicable:

# Fragile X CGG Repeat Analysis (Analytical Detection Rate >99%)

PCR amplification using Asuragen, Inc. AmplideX® *FMR1* PCR reagents followed by capillary electrophoresis for allele sizing was performed. Samples positive for *FMR1* CGG repeats in the premutation and full mutation size range were further analyzed by Southern blot analysis to assess the size and methylation status of the *FMR1* CGG repeat.

# Genotyping (Analytical Detection Rate >99%)

Multiplex PCR amplification and allele specific primer extension analyses using the MassARRAY® System were used to identify variants that are complex in nature or are present in low copy repeats. Rare sequence variants may interfere with assay performance.

# Multiplex Ligation-Dependent Probe Amplification (MLPA) (Analytical Detection Rate >99%)





MLPA® probe sets and reagents from MRC-Holland were used for copy number analysis of specific targets versus known control samples. False positive or negative results may occur due to rare sequence variants in target regions detected by MLPA probes. Analytical sensitivity and specificity of the MLPA method are both 99%.

For alpha thalassemia, the copy numbers of the *HBA1* and *HBA2* genes were analyzed. Alpha-globin gene deletions, triplications, and the Constant Spring (CS) mutation are assessed. This test is expected to detect approximately 90% of all alpha-thalassemia mutations, varying by ethnicity. Carriers of alpha-thalassemia with three or more *HBA* copies on one chromosome, and one or no copies on the other chromosome, may not be detected. With the exception of triplications, other benign alpha-globin gene polymorphisms will not be reported. Analyses of *HBA1* and *HBA2* are performed in association with long-range PCR of the coding regions followed by short-read sequencing.

For Duchenne muscular dystrophy, the copy numbers of all *DMD* exons were analyzed. Potentially pathogenic single exon deletions and duplications are confirmed by a second method. Analysis of *DMD* is performed in association with sequencing of the coding regions.

For congenital adrenal hyperplasia, the copy number of the *CYP21A2* gene was analyzed. This analysis can detect large deletions due to unequal meiotic crossing-over between *CYP21A2* and the pseudogene *CYP21A1P*. These 30-kb deletions make up approximately 20% of *CYP21A2* pathogenic alleles. This test may also identify certain point mutations in *CYP21A2* caused by gene conversion events between *CYP21A2* and *CYP21A2* and *CYP21A1P*. Some carriers may not be identified by dosage sensitive methods as this testing cannot detect individuals with two copies (duplication) of the *CYP21A2* gene on one chromosome and loss of *CYP21A2* (deletion) on the other chromosome. Analysis of *CYP21A2* is performed in association with long-range PCR of the coding regions followed by short-read sequencing.

For spinal muscular atrophy (SMA), the copy numbers of the *SMN1* and *SMN2* genes were analyzed. The individual dosage of exons 7 and 8 as well as the combined dosage of exons 1, 4, 6 and 8 of *SMN1* and *SMN2* were assessed. Copy number gains and losses can be detected with this assay. Depending on ethnicity, 6 - 29 % of carriers will not be identified by dosage sensitive methods as this testing cannot detect individuals with two copies (duplication) of the *SMN1* gene on one chromosome and loss of *SMN1* (deletion) on the other chromosome (silent 2+0 carrier) or individuals that carry an intragenic mutation in *SMN1*. Please also note that 2% of individuals with SMA have an *SMN1* mutation that occurred *de novo*. Typically in these cases, only one parent is an SMA carrier.

The presence of the c.\*3+80T>G (chr5:70.247.901T>G) variant allele in an individual with Ashkenazi Jewish or Asian ancestry is typically indicative of a duplication of *SMN1*. When present in an Ashkenazi Jewish or Asian individual with two copies of *SMN1*, c.\*3+80T>G is likely indicative of a silent (2+0) carrier. In individuals with two copies of *SMN1* with African American, Hispanic or Caucasian ancestry, the presence or absence of c.\*3+80T>G significantly increases or decreases, respectively, the likelihood of being a silent 2+0 silent carrier.

Pathogenic or likely pathogenic sequence variants in exon 7 may be detected during testing for the c.\*3+80T>G variant allele; these will be reported if confirmed to be located in SMN1 using locus-specific Sanger primers

Pathogenic or likely pathogenic sequence variants in exon 7 may be detected during testing for the c.\*3+80T>G variant allele; these will be reported if confirmed to be located in SMN1 using locus-specific Sanger primers.

MLPA for Gaucher disease (*GBA*), cystic fibrosis (*CFTR*), and non-syndromic hearing loss (*GJB2/GJB6*) will only be performed if indicated for confirmation of detected CNVs. If *GBA* analysis was performed, the copy numbers of exons 1, 3, 4, and 6 - 10 of the *GBA* gene (of 11 exons total) were analyzed. If *CFTR* analysis was performed, the copy numbers of all 27 *CFTR* exons were analyzed. If *GJB2/GJB6* analysis was performed, the copy numbers of all 27 *CFTR* exons were analyzed. If *GJB2/GJB6* analysis was performed, the copy numbers of all 27 *CFTR* exons were analyzed. If *GJB2/GJB6* analysis was performed, the copy numbers of all 27 *CFTR* exons were analyzed. If *GJB2/GJB6* analysis was performed, the copy numbers of all 27 *CFTR* exons were analyzed. If *GJB2/GJB6* analysis was performed, the copy number of the two *GJB2* exons were analyzed, as well as the presence or absence of the two upstream deletions of the *GJB2* regulatory region, del(*GJB6* -D13S1830) and del(*GJB6* -D13S1854).

#### Next Generation Sequencing (NGS) (Analytical Detection Rate >95%)

NGS was performed on a panel of genes for the purpose of identifying pathogenic or likely pathogenic variants.

Agilent SureSelect<sup>TM</sup>QXT technology was used with a custom capture library to target the exonic regions and intron/exon splice junctions of the relevant genes, as well as a number of UTR, intronic or promoter regions that contain previously reported mutations. Samples were pooled and sequenced on the Illumina HiSeq 2500 platform in the Rapid Run mode or the Illumina NovaSeq platform in the Xp workflow, using 100 bp paired-end reads. The sequencing data was analyzed using a custom bioinformatics algorithm designed and validated in house. The coding exons and splice junctions of the known protein-coding RefSeq genes were assessed for the average depth of coverage (minimum of 20X) and data quality threshold values. Most exons not meeting a minimum of >20X read depth across the exon are further analyzed by Sanger sequencing. Please note that several genomic regions present difficulties in mapping or obtaining read depth >20X. The exons contained within these regions are noted within Table 1 (as "Exceptions") and will not be reflexed to Sanger sequencing if the mapping quality or coverage is poor. Any variants identified during testing in these regions are confirmed by a second method and reported if determined to be pathogenic or likely pathogenic. However, as there is a possibility of false negative results within these regions, detection rates and residual risks for these genes have been calculated with the presumption that variants in these exons will not be detected, unless included in the MassARRAY® genotyping platform.

This test will detect variants within the exons and the intron-exon boundaries of the target regions. Variants outside these regions may not be detected, including, but not limited to, UTRs, promoters, and deep intronic areas, or regions that fall into the Exceptions mentioned above. This





technology may not detect all small insertion/deletions and is not diagnostic for repeat expansions and structural genomic variation. In addition, a mutation(s) in a gene not included on the panel could be present in this patient.

Variant interpretation and classification was performed based on the American College of Medical Genetics Standards and Guidelines for the Interpretation of Sequence Variants (Richards et al, 2015). All potentially pathogenic variants may be confirmed by either a specific genotyping assay or Sanger sequencing, if indicated. Any benign variants, likely benign variants or variants of uncertain significance identified during this analysis will not be reported.

#### Copy Number Variant Analysis (Analytical Detection Rate >95%)

Large duplications and deletions were called from the relative read depths on an exon-by-exon basis using a custom exome hidden Markov model (XHMM) algorithm. Deletions or duplications determined to be pathogenic or likely pathogenic were confirmed by either a custom arrayCGH platform, quantitative PCR, or MLPA (depending on CNV size and gene content). While this algorithm is designed to pick up deletions and duplications of 2 or more exons in length, potentially pathogenic single-exon CNVs will be confirmed and reported, if detected.

# Exon Array (Confirmation method) (Accuracy >99%)

The customized oligonucleotide microarray (Oxford Gene Technology) is a highly-targeted exon-focused array capable of detecting medically relevant microdeletions and microduplications at a much higher resolution than traditional aCGH methods. Each array matrix has approximately 180,000 60-mer oligonucleotide probes that cover the entire genome. This platform is designed based on human genome NCBI Build 37 (hg19) and the CGH probes are enriched to target the exonic regions of the genes in this panel.

# Quantitative PCR (Confirmation method) (Accuracy >99%)

The relative quantification PCR is utilized on a Roche Universal Library Probe (UPL) system, which relates the PCR signal of the target region in one group to another. To test for genomic imbalances, both sample DNA and reference DNA is amplified with primer/probe sets that specific to the target region and a control region with known genomic copy number. Relative genomic copy numbers are calculated based on the standard  $\Delta\Delta$ Ct formula.

# Long-Range PCR (Analytical Detection Rate >99%)

Long-range PCR was performed to generate locus-specific amplicons for *CYP21A2*, *HBA1* and *HBA2* and *GBA*. The PCR products were then prepared for short-read NGS sequencing and sequenced. Sequenced reads were mapped back to the original genomic locus and run through the bioinformatics pipeline. If indicated, copy number from MLPA was correlated with the sequencing output to analyze the results. For *CYP21A2*, a certain percentage of healthy individuals carry a duplication of the *CYP21A2* gene, which has no clinical consequences. In cases where two copies of a gene are located on the same chromosome in tandem, only the second copy will be amplified and assessed for potentially pathogenic variants, due to size limitations of the PCR reaction. However, because these alleles contain at least two copies of the *CYP21A2* gene in tandem, it is expected that this patient has at least one functional gene in the tandem allele and this patient is therefore less likely to be a carrier. When an individual carries both a duplication allele and a pathogenic variant, or multiple pathogenic variants, the current analysis may not be able to determine the phase (cis/trans configuration) of the *CYP21A2* alleles identified. Family studies may be required in certain scenarios where phasing is required to determine the carrier status.

## **Residual Risk Calculations**

Carrier frequencies and detection rates for each ethnicity were calculated through the combination of internal curations of >28,000 variants and genomic frequency data from >138,000 individuals across seven ethnic groups in the gnomAD database. Additional variants in HGMD and novel deleterious variants were also incorporated into the calculation. Residual risk values are calculated using a Bayesian analysis combining the *a priori* risk of being a pathogenic mutation carrier (carrier frequency) and the detection rate. They are provided only as a guide for assessing approximate risk given a negative result, and values will vary based on the exact ethnic background of an individual. This report does not represent medical advice but should be interpreted by a genetic counselor, medical geneticist or physician skilled in genetic result interpretation and the relevant medical literature.

#### Sanger Sequencing (Confirmation method) (Accuracy >99%)

Sanger sequencing, as indicated, was performed using BigDye Terminator chemistry with the ABI 3730 DNA analyzer with target specific amplicons. It also may be used to supplement specific guaranteed target regions that fail NGS sequencing due to poor quality or low depth of coverage (<20 reads) or as a confirmatory method for NGS positive results. False negative results may occur if rare variants interfere with amplification or annealing.

Please note these tests were developed and their performance characteristics were determined by Mount Sinai Genomics, Inc. They have not been cleared or approved by the FDA. These analyses generally provide highly accurate information regarding the patient's carrier or affected status. Despite this high level of accuracy, it should be kept in mind that there are many potential sources of diagnostic error, including misidentification of samples, polymorphisms, or other rare genetic variants that interfere with analysis. Families should understand that rare diagnostic errors may occur for these reasons.

#### SELECTED REFERENCES





# Carrier Screening

Grody W et al. ACMG position statement on prenatal/preconception expanded carrier screening. Genet Med. 2013 15:482-3.

# Fragile X syndrome:

Chen L et al. An information-rich CGG repeat primed PCR that detects the full range of Fragile X expanded alleles and minimizes the need for Southern blot analysis. *J Mol Diag* 2010 12:589-600.

# Spinal Muscular Atrophy:

Luo M et al. An Ashkenazi Jewish SMN1 haplotype specific to duplication alleles improves pan-ethnic carrier screening for spinal muscular atrophy. *Genet Med*. 2014 16:149-56.

#### Ashkenazi Jewish Disorders:

Scott SA et al. Experience with carrier screening and prenatal diagnosis for sixteen Ashkenazi Jewish Genetic Diseases. Hum. Mutat. 2010 31:1-11.

## Duchenne Muscular Dystrophy:

Flanigan KM et al. Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohort. *Hum Mutat* . 2009 30:1657-66.

## Variant Classification:

Richards S et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med.* 2015 May;17(5):405-24 Additional disease-specific references available upon request.